BPC-157 vs Vasoactive Intestinal Peptide (VIP)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It has been extensively studied in animal models for tissue repair, gastroprotection, and tendon/ligament/muscle healing. Important: essentially all efficacy data are preclinical (rodent), there are no completed published human efficacy trials, and it is prohibited in sport by WADA.
Full profileVasoactive Intestinal Peptide (VIP)
28-amino acid neuropeptide found throughout the CNS, gut, and immune system. Functions as a potent anti-inflammatory, vasodilator, and neurotrophic factor. Research applications include CIRS (Chronic Inflammatory Response Syndrome), pulmonary arterial hypertension, autoimmune conditions, and gut motility disorders. Intranasal administration is most studied for CIRS and neuroinflammatory conditions.
Full profile| BPC-157 | Vasoactive Intestinal Peptide (VIP) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Body Protection Compound 157, PL 14736, Pentadecapeptide BPC 157 | VIP, vasoactive intestinal polypeptide, PHM-27 |
| Evidence | Preclinical only | Investigational (in trials) |
| Dosing range | 200mcg–1000mcg mcg, once or twice daily | 25mcg–100mcg mcg, Daily intranasal or 1–2x weekly subcutaneous |
| Administration | Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols) | Intranasal spray, Subcutaneous injection, Inhalation (nebulized) |
| Key side effects | Nausea (rare, typically at higher doses), Dizziness / lightheadedness shortly after injection (uncommon, anecdotal), Injection site redness or irritation, Human safety profile is not established — no controlled human trials | Facial flushing, Transient hypotension, Nasal irritation (intranasal route), Tachycardia |
| Cited sources | 6 references | 2 references |
Key differences
- Evidence level differs: BPC-157 is preclinical only, while Vasoactive Intestinal Peptide (VIP) is investigational (in trials).
- Administration: BPC-157 — Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols); Vasoactive Intestinal Peptide (VIP) — Intranasal spray, Subcutaneous injection, Inhalation (nebulized).
- Frequency: BPC-157 is typically once or twice daily; Vasoactive Intestinal Peptide (VIP) is Daily intranasal or 1–2x weekly subcutaneous.
- Research depth: this profile cites 6 sources for BPC-157 vs 2 for Vasoactive Intestinal Peptide (VIP).
How each works
BPC-157
Preclinical rodent and in-vitro studies — predominantly from the Sikiric group in Zagreb, with mechanistic angiogenesis work from Pang's group in Taiwan — report accelerated healing of tendon, ligament, muscle, and gut tissue. Proposed mechanisms include modulation of the nitric oxide (NO) system, promotion of angiogenesis via the VEGFR2–Akt–eNOS pathway, upregulation of growth factor signaling, and effects along the gut–brain axis. Despite a large and internally consistent animal literature, BPC-157 has no completed human clinical efficacy trials and is an unapproved drug.
Vasoactive Intestinal Peptide (VIP)
VIP activates VPAC1 and VPAC2 receptors coupled to cAMP, suppressing pro-inflammatory cytokines while promoting Th2 regulatory immune responses and Treg differentiation. In the CIRS/biotoxin illness framework pioneered by Shoemaker, VIP intranasal formulation demonstrates normalization of inflammatory markers and improvement in TGF-β, MSH, and VIP deficiency seen in CIRS patients. Pulmonary vasodilation effects have been studied for PAH.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.